Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 11 years
- Director since
- 2023
11 years of board service in total across 4 boards, counting each seat separately. Longest: Sarepta Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Gain Therapeutics Inc. June 24, 202694.5%
-
Filana Therapeutics Inc. June 11, 202685.7%
-
Gain Therapeutics Inc. June 24, 202599.5%
-
Sarepta Therapeutics Inc. June 5, 202595.5%
-
Gain Therapeutics Inc. June 24, 202469.4%
-
Gain Therapeutics Inc. June 23, 202397.6%
-
Sarepta Therapeutics Inc. June 8, 202383.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 4, 2026 | Sarepta Therapeutics Inc. | Grant or award | +16,875 | — | — |
| Jan 29, 2026 | Sarepta Therapeutics Inc. | Option exercise | +10,500 | $13.71 | $143,955 |
| Jan 29, 2026 | Sarepta Therapeutics Inc. | Shares withheld for tax | −6,780 | $21.23 | $143,939 |
| Mar 12, 2025 | Sarepta Therapeutics Inc. | Option exercise | +9,746 | $25.18 | $245,404 |
| Mar 12, 2025 | Sarepta Therapeutics Inc. | Open-market sale | −2,491 | $99.64 | $248,203 |
| Mar 10, 2025 | Sarepta Therapeutics Inc. | Grant or award | +2,383 | — | — |
| Mar 1, 2024 | Sarepta Therapeutics Inc. | Grant or award | +1,846 | — | — |
| Mar 6, 2023 | Sarepta Therapeutics Inc. | Grant or award | +1,523 | — | — |
Questions about Claude Nicaise
What boards is Claude Nicaise on?
Claude Nicaise sits on the boards of Chemomab Therapeutics Ltd. American Depositary Share, Filana Therapeutics Inc., Gain Therapeutics Inc. and Sarepta Therapeutics Inc.
How long has Claude Nicaise served on boards?
Our records show at least 11 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.